Two vaccines are approved against mpox: MVA-BN and LC16. These vaccines are based on weakened versions of a related orthopoxvirus (vaccinia) and were developed against smallpox. However, availability ...

One of these commonly discussed concerns is roseola. Roseola is a herpes family virus, a group of viruses that cause infections in humans and animals. It commonly affects little children under 2 years ...

In 2009 I joined the laboratory of Geoffrey Smith at Imperial College London and subsequently the University of Cambridge to study vaccinia virus modulation of innate immunity and cell death. In 2014 ...

GEO-CM04S1 BARDA/Project NextGen Phase 2b trial preparations ongoing with manufacturing of clinical trial materials underway and clinical sites confirmed Additional data evaluating GEO-CM04S1 as ...

Preliminary results from the phase 1b/2 Olvi-Vec-SCLC-202 trial show that adding olvimulogene nanivacirepvec (olvi-vec; GL-ONC1), a modified oncolytic vaccinia virus, to platinum-based chemotherapy ...

Olvi-Vec (olvimulogene nanivacirepvec), Genelux’s most advanced product candidate is a proprietary, modified oncolytic vaccinia virus, a stable DNA virus with a large engineering capacity. Genelux is ...

WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an ...

- U.S. Food and Drug Administration states that data from the ongoing OnPrime/GOG-3076 Phase 3 registrational trial could potentially support traditional approval- WESTLAKE VILLAGE, Calif., March ...